TY - JOUR AU1 - Alessi, David M. AU2 - Hutcherson, Robert W. AU3 - Mickel, Robert A. AB - Abstract • Lymphokine-activated killer cells are thought to be important mediators of host tumor defense. In the present study, the cytotoxic potential of lymphokine-activated lymphocytes against different head and neck squamous cell carcinoma cell lines was investigated. Lymphokine-activated killer cells were derived from peripheral blood lymphocytes. Effector peripheral blood lymphocyte cell suspensions were incubated in the presence or absence of recombinant interleukin-2. Cytotoxicity of incubated cells or fresh peripheral blood lymphocytes was determined in a 3-hour chromium 51 release assay. Target cell lines included K562 (a natural killer–sensitive target) and the following head and neck squamous cell carcinoma cell lines: Cal 27, UMSCC-1, UMSCC-8, UMSCC-16, UMSCC-19, and UMSCC-22a. Fresh peripheral blood lymphocytes and peripheral blood lympho References 1. Lundy J, Wanebo H, Pinsky C, et al. Delayed hypersensitivity reactions in patients with squamous cell cancer of the head and neck . Am J Surg. 1974;128:530-533.Crossref 2. Eilber FR, Morton DL, Ketcham AS. Immunologic abnormalities in head and neck cancer . Am J Surg. 1974;128:534-537.Crossref 3. Kessler DJ, Mickel RA, Lichtenstein A. Depressed natural killer cell activity in cervical lymph nodes containing focal metastatic squamous cell carcinoma . Arch Otolaryngol Head Neck Surg. 1988;114:313-318.Crossref 4. Vinzenz K, Micksche M. Natural cytotoxicity in draining lymph nodes of squamous cell cancer in the maxillofacial region . J Oral Maxillofac Surg. 1987;45:42-47.Crossref 5. Tilden AB, Itoh K, Balch CM. Human lymphokine-activated killer cells: identification of two types of effector cells . J Immunol . 1987; 138:1068-1073. 6. Lotzova E, Savary CA, Freedman R, et al. Natural immunity against ovarian tumors . Comp Immunol Microbiol Infect Dis . 1986;2:269-275.Crossref 7. Itoh K, Tilden AB, Balch CM. Lysis of human solid tumor cells by lymphokine-activated natural killer cells . J Immunol . 1986; 136:3910-3915. 8. Rosenberg SA. The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2 . Semin Oncol . 1986;13:200-206. 9. Boyum A. Isolation of mononuclear cells and of granulocytes from human blood: isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g . Scand J Clin Lab Invest . 1968;21( (suppl 97) ):77.Crossref 10. Krause CJ, Carey TE, Ott RW, Hurbis C, McClatchey KD, Regezi JA. Human squamous cell carcinoma: establishment and characterization of new permanent cell lines . Arch Otolaryngol Head Neck Surg . 1981;107:703-710.Crossref 11. Brunner KT, Engers HD, Cerotinni JC. The chromium-51 release assay as used for the quantitative measurement of cell-mediated cytolysis in vitro . In: Bloom BR, David JR, eds. In Vitro Methods in Cell-Mediated Immunity . Orlando, Fla: Academic Press Inc; 1976:423-428. 12. Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS. Spontaneous human lymphocytemediated cytotoxicity against tumor target cells, IX: the quantitation of natural killer cell activity . J Clin Immunol . 1981;1:51.Crossref 13. Bloom ET, Korn EL. Quantification of natural cytotoxicity by human lymphocyte subpopulations isolated by density heterogeneity of the effector cells . J Immunol Methods . 1983;58:323.Crossref 14. Jennrich R. Nonlinear regression . In: Dixon WJ, ed. BMDP Statistical Software, 1981 . Berkeley, Calif: University of California Press; 1981:290-304. 15. Jennrich R, Sampson P. General mixed model analysis of variance . In: Dixon WJ, ed. BMDP Statistical Software, 1981 . Berkeley, Calif: University of California Press; 1981:413-426. 16. Robinson BW, Morstyn G. Natural killer–resistant human lung cancer cells are lysed by recombinant interleukin-2-activated NK cells . Cell Immunol . 1987;106:215-222.Crossref 17. Ting CC, Hargrove ME, Stephany D. Generation of activated killer cells in tumor bearing hosts . Int J Cancer . 1987;39:232-239.Crossref 18. Parhar RS, Lala PK, Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin-2 . J Exp Med. 1987;165:14-28.Crossref 19. Rodolfo M, Parmiani G. Growth inhibition of murine colonic adenocarcinoma by tumor immune but not by IL-2–activated or alloactivated lymphocytes . Tumori . 1987;73:1-9. 20. Grimm EA. Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality . Biochim Biophys Acta . 1986;865:267-279. 21. Forni G, Giovarelli M, Santoni A, Modesti A, Forni M. Tumour inhibition by interleukin-2 at the tumour/host interface . Biochim Biophys Acta . 1986;865:307-327. 22. Woodruff MFA. The cytolytic and regulatory role of natural killer cells in experimental neoplasia . Biochim Biophys Acta . 1986;865:43-57. 23. Allavena P, Meredino A, Bello MD, et al. Mechanisms of natural cell-mediated resistance in human solid tumors . Biochim Biophys Acta . 1986;865:281-288. 24. Evans R. The immunologic network at the site of tumor rejection . Biochim Biophys Acta . 1986;865:1-11. 25. Heberman RB. Adoptive therapy for cancer with interleukin-2–activated killer cells . Cancer Bull. 1987;39:6-13. 26. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes . Science . 1986;233:1318-1321.Crossref TI - Production of Lymphokine-Activated Lymphocytes: Lysis of Human Head and Neck Squamous Cell Carcinoma Cell Lines JF - Archives of Otolaryngology - Head & Neck Surgery DO - 10.1001/archotol.1989.01860300079022 DA - 1989-06-01 UR - https://www.deepdyve.com/lp/american-medical-association/production-of-lymphokine-activated-lymphocytes-lysis-of-human-head-and-REfXY1e8DP SP - 725 EP - 730 VL - 115 IS - 6 DP - DeepDyve ER -